OncologyTube Professional - Patients Click Here
15,287 video views
BeaconMedIC: Videos
09:06
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients with advanced NSCLC on daily steroids while receiving an immune checkpoint inhibitor against PD-1 or PD-L1.
by:BeaconMedIC | 26 views
12:37
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pem​etrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positi​ve advanced NSCLC.
by:BeaconMedIC | 60 views
07:04
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positi​ve NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first line treatment.
by:BeaconMedIC | 40 views
10:15
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizumab (Avastin), which shows a consistent improvement in progression-fre​e survival but not overall survival.
by:BeaconMedIC | 118 views
07:11
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR mutation-positi​ve patients with high tumor PD-L1 expression, which led to poor outcomes that should cast a long shadow on this approach.
by:BeaconMedIC | 273 views
08:09
Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the carboplatin/nab​-paclitaxel/ate​zolizumab combination is a strong treatment option in this patient setting.
by:BeaconMedIC | 136 views
08:56
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipili​mumab (nivo/ipi) combination in patients with low PD-L1 and high tumor mutation burden (TMB).
by:BeaconMedIC | 300 views
09:32
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunothe​rapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting.
by:BeaconMedIC | 347 views
11:05
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation in the Plenary Session at ASCO 2018, clinical implications, & whether it should change practice.
by:BeaconMedIC | 632 views
07:12
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.
by:BeaconMedIC | 996 views
dsfsd